Why Key Analyst Sees Buffalo Wild Wings Rising Another 15%
Oppenheimer weighed in on Buffalo Wild Wings' position going forward and was fairly positive on the outlook.
All Work
Chris Lange
How a Fast Track Designation Saved Corbus Pharma
Corbus Pharmaceuticals may have found its saving grace in a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Staples: Are In-Line Earnings, Store Closures Good Enough?
Staples released its fiscal second-quarter earnings report and updated its store closures count before the markets opened Wednesday.
Target Rises on Solid Earnings Beat
Target reported better-than-expected fiscal second-quarter financial results Wednesday before the markets opened.
Analog Devices Rises on Solid Earnings Beat and Guidance
ThinkstockAnalog Devices, Inc. (NASDAQ: ADI) reported its fiscal third quarter financial results after the markets closed on Tuesday. The company had $0.77 in earnings per share (EPS) on $863 million in revenue compared to…
How One Key Analyst Sees Activision Blizzard Rising After Earnings
James Woodson/ThinkStockActivision Blizzard, Inc. (NASDAQ: ATVI) absolutely crushed its most recent earnings report. As a result, analyst calls came pouring in for the video game giant, all very positive on the outlook for the…
What to Expect From Staples Earnings
Wikimedia CommonsStaples, Inc. (NASDAQ: SPLS) is set to report its fiscal second-quarter financial results Wednesday before the markets open. Thomson Reuters has consensus estimates calling for $0.12 in earnings per share (EPS) on $4.96 billion…
Can Target Keep Hitting the Mark for Earnings?
courtesy of Target Corp.Target Corp. (NYSE: TGT) is scheduled to report its fiscal second quarter financial results before the markets open on Wednesday. The consensus estimates from Thomson Reuters call for $1.11 in earnings…
Omeros Shares Doubling on Positive Phase 2 Data
ThinkstockOmeros Corp. (NASDAQ: OMER) is flying high in Tuesday’s trading session with shares practically doubling on positive phase 2 news. The company announced additional positive data in the it’s phase 2 clinical trial of…
Esperion Updates Phase 2 Study and Keeps Volatility Traders Interested
ThinkstockEsperion Therapeutics, Inc. (NASDAQ: ESPR) had a huge move in Monday’s trading session as the result of an analyst upgrade but it looks like this company has kept the rally alive into Tuesday with…
Are Home Depot Earnings Really Good Enough For All-Time Highs?
Wikimedia CommonsThe Home Depot, Inc. (NYSE: HD) reported its fiscal second quarter financial results before the markets opened on Tuesday. The home improvement giant had $1.71 in earnings per share (EPS) on $24.8 billion…
Aclaris Gets Ready For Its Initial Public Offering
ThinkstockAclaris Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given for the filing but the offering is valued up…
Urban Outfitters Rises on Earnings Beat
Wikimedia CommonsUrban Outfitters Inc. (NASDAQ: URBN) released its fiscal second quarter financial results after the markets closed on Monday. The retailer had $0.52 in earnings per share (EPS) on $867.5 million in revenue compared…
SynCardia Prepares For IPO
Thinkstock Medical device maker SynCardia Systems, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given in the filing but the offering…
Why the Earnings Bar Is Set Lower for Lowe’s Than Home Depot
Both Home Depot and Lowe's are reporting earnings this week. 24/7 Wall St. thought it would be appropriate to compare each ahead of earnings.
Are Zulily Shareholders Getting Enough in the QVC Buyout?
Liberty Interactive and Zulily announced that they have entered into a definitive agreement under which the former will acquire all outstanding shares of the latter.
Philip Morris Scores Key Upgrade With Dividend Hike Expectations
Philip Morris International might be looking to entice more investors with an even stronger dividend, or at least one key analyst thinks so.
Kite Pharma Updates Study, Dispells Rumors
Kite Pharma gave an update from its ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma.
Is AVEO the Next Aquinox for Traders?
Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.
The Top 7 Earnings Reports for the Week Ahead
24/7 Wall St. has put together a preview of Wal-Mart and some of the other major companies reporting their quarterly results this week.